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Abstract
Background: Lower respiratory infections are among the top ten causes of death worldwide. Since pathogen to
cell adhesion is a crucial step in the infection progress, blocking the interaction between eukaryotic receptors and
bacterial ligands may enable the pathogenesis process to be stopped. Cell surface glycosaminoglycans (GAGs) are
known to be mediators in the adhesion of diverse bacteria to different cell types, making it of interest to
examine their involvement in the attachment of various pathogenic bacteria to lung cells, including epithelial
cells and fibroblasts.
Methods: The function of cell surface GAGs in bacterial adhesion was studied by reducing their levels through
inhibiting their biosynthesis and enzymatic degradation, as well as in binding competition experiments with
various species of GAGs. The participation of the different bacterial adhesins in attachment was evaluated
through competition with two peptides, both containing consensus heparin binding sequences. Blocking
inhibition assays using anti-syndecans and the enzymatic removal of glypicans were conducted to test their
involvement in bacterial adhesion. The importance of the fine structure of GAGs in the interaction with
pathogens was investigated in competition experiments with specifically desulfated heparins.
Results: The binding of all bacteria tested decreased when GAG levels in cell surface of both lung cells were
diminished. Competition experiments with different types of GAGs showed that heparan sulfate chains are the
main species involved. Blocking or removal of cell surface proteoglycans evidenced that syndecans play a more
important role than glypicans. The binding was partially inhibited by peptides including heparin binding
sequences. Desulfated heparins also reduced bacterial adhesion to different extents depending on the
bacterium and the sulfated residue, especially in fibroblast cells.
Conclusions: Taken together, these data demonstrate that the GAG chains of the cell surface are involved in
the adhesion of bacterial adhesins to lung cells. Heparan sulfate seems to be the main species implicated, and
binding is dependent on the sulfation pattern of the molecule. These data could facilitate the development of
new anti-infective strategies, enabling the development of new procedures for blocking the interaction
between pathogens and lung cells more effectively.
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Background
Currently, infectious pathologies remain an important
health problem, being among the 10 leading causes of
death worldwide [1]. In addition to the infectious dis-
eases not yet eradicated, emerging and re-emerging
infections may also appear. This is frequently due to
multiple factors including environmental changes, lack
of prevention measures, travel and global trade, alter-
ations in host susceptibility and, particularly, adaptive
genetic changes in the microorganisms themselves [2].
New adaptations in causative agents provide them with
a temporary evolutionary advantage against environmen-
tal factors, host defenses and antimicrobial drugs [2, 3],
as in the case of some Staphylococcus aureus strains,
which have acquired resistance to multiple antibiotics,
resulting in it becoming the leading cause of chronic in-
fections associated with indwelling medical devices [4].
Of the myriad communicable pathologies currently af-
fecting humankind, the World Health Organization has
highlighted the threat from lower respiratory infections
and tuberculosis, both of which continue to be among
the global top ten causes of death [1]. Although infec-
tions of the lower respiratory tract are caused by a var-
iety of pathogens including viruses and fungi, bacteria
are the main causative agents [5].
The human body is largely exposed to different bacter-
ial pathogens through the skin and mucous membranes,
including the respiratory mucosa [6]. After using a suit-
able portal of entry, the microorganisms must reach
their target site in the body and accomplish the most
critical step, the establishment of the focus of the infec-
tion. This crucial process implies that bacterial patho-
gens are capable of adhering to and remaining attached
to the cell surface without being dislodged by host de-
fenses [7, 8]. Pathogenic microorganisms have devel-
oped diverse virulence factors, and these may cooperate
to accomplish the establishment of a pathogen through
mediation of the adhesion and colonization phases,
through promoting tissue damage and through spread-
ing the pathogen and overcoming the host immune
system [7, 8].
Bacterial adhesins need to recognize and interact spe-
cifically with host cell surface receptors in order to
achieve adequate adherence and colonization [6].
Eukaryotic receptors may also be involved in subsequent
stages of the infectious process, including invasiveness,
organotropism, and interference in host defense response
[7]. A variety of cell surface molecules can act as receptors
for microorganisms, including proteins, carbohydrates,
lipids, and various different combinations of these.
Proteoglycans (PGs) are a type of glycoconjugate that act
as receptors for multiple microbial pathogens [9]. These
complex molecules are composed of long unbranched
chains of polysaccharides called glycosaminoglycans
(GAGs), which are covalently attached to a wide variety
of core proteins [10]. These molecules possess a high
negative charge, and are formed by repeating units of
uronic acid or galactose and an amino sugar, either N-
acetyl glucosamine or N-acetylgalactosamine. There are
four major classes of GAGs: heparin/heparan sulfate
(HP/HS), chondroitin sulfate (CS), keratan sulfate, and
hyaluronic acid, the latter being the only one not cova-
lently bound to a core protein [10]. GAGs display
remarkable structural diversity, which is the result of
interrelated enzymatic reactions, including N- and O-
sulfations and epimerization, that occur heteroge-
neously along the chain [11, 12]. Due to the diversity of
core proteins, and especially to the diversity of compos-
ition patterns, length, epimerization and sulfation of
saccharide chains, the PGs have great heterogeneity,
which enables them to fulfil numerous functions. Modi-
fications in GAG chains create specific binding motifs
for many ligands, such as cytokines, chemokines, growth
factors, enzymes and enzyme inhibitors, and extracellular
matrix (ECM) proteins [13–17]. These molecules are also
involved in several physiological activities, including
organization of the ECM, regulation of proliferation, dif-
ferentiation and morphogenesis, cytoskeletal organization,
tissue repair, inflammation and vascularization [18–20]. In
addition, a variety of roles have been ascribed to these
molecules in pathological process, including non-
infectious pathologies such as cancer [21, 22] as well as
infectious pathologies generated by diverse pathogens
[23, 24]. Different types of pathogen recognize GAGs as
receptors, including a wide spectrum of viruses, bac-
teria and parasites [24–26].
In addition to their remarkable heterogeneity, PGs are
ubiquitous, and are widely distributed on cell surfaces,
in pericellular locations and in cytoplasmic secretory
vesicles [10, 13]. The expression and composition of
GAGs are variable, depending on the cell type and the
physiological conditions [25]. These features make PGs
excellent candidates as host receptors for microorgan-
isms, with microbial pathogens showing a preference for
interacting with HS chains attached to cell surface pro-
teoglycans (HSPGs), and principally with respect to two
families: the transmembrane syndecans (SDCs) and the
glycosylphosphoinositide-linked glypicans (GPCs), which
have four and six members respectively [26, 27].
GAGs play significant roles in many pathophysio-
logical processes in the ECM of the lung: regulating
hydration and water homeostasis, maintaining struc-
ture and function, modulating the inflammatory re-
sponse, and influencing tissue repair and remodeling
[28]. Many studies have described the roles played by
PGs in a wide range of pulmonary diseases, including
malignant mesothelioma, pulmonary edema, fibrosis,
asthma, emphysema, and bronchiectasis [28–31].
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The aim of this article is to investigate the involvement
of PGs and their GAG chains as receptors for certain
common respiratory bacterial pathogens. The study ana-
lyzes the role played by different molecular species of
PGs in bacterial adherence, as well as the importance of
specific molecular aspects of GAG chain structure on
their interaction with microorganisms, particularly the
influence of sulfation of saccharide chain residues. The
analysis was carried out using both epithelial cells and fi-
broblasts of pulmonary origin since different profiles of
cell surface GAGs are to be expected for the two cell
types. Ultimately, understanding the complexity of the
adhesion process would allow for the possibility of bac-
terial infections to be controlled via preventing the adhe-
sion or invasion stages of bacterial pathogenesis.
Methods
Materials
The following materials were purchased from the manu-
facturers indicated: heparin, heparan sulfate, chondroitin
sulfate A, B and C, heparinases I and III, chondroitinase
ABC, fluorescein isothiocyanate (FITC), GenElute PCR
clean-up kit, phospholipase C phosphatidylinositol-specific
(PI-PLC) from Bacillus cereus, all from Sigma-Aldrich (St.
Louis, MO, USA); 2-O, 6-O and N-desulfated heparins
from Amsbio (Abingdon, UK); Dulbecco’s Modified Eagle’s
minimal essential medium (DMEM) and Minimum Es-
sential Medium (MEM), fetal bovine serum, penicillin-
streptomycin, and PBS-phosphate-buffered saline from
Gibco-Thermo Fischer Scientific (Waltham, MA, USA);
Brain-Heart Infusion broth from Pronadisa (Madrid,
Spain); RNeasy Kit and RNase-Free DNase from Qiagen
(Hilden, Germany); High-Capacity cDNA Reverse Tran-
scription Kit and PowerSYBR Green PCR Master Mix
from Applied Biosystems (Foster City, CA, USA). Syn-
thetic peptides were from Abyntek Biopharma (Derio,
Spain); mouse monoclonal anti-syndecan 1 (CD138)
from DakoCytomation (Carpinteria, CA, USA); and
rabbit anti-syndecan 2, goat anti-syndecan 3 and rabbit
anti-syndecan 4 polyclonal antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All other chemi-
cals were obtained from commercial sources and were
of analytical grade.
Bacterial strains, cell lines and culture conditions
The species used in this study were the Gram-positive
bacteria Staphylococcus aureus, Streptococcus pyogenes,
Streptococcus pneumoniae and Enterococcus faecalis, and
the Gram-negative bacteria Escherichia coli, Klebsiella
pneumoniae and Serratia marcescens, all of which were
obtained from the Hospital Universitario Central de
Asturias. All the bacteria were grown in Brain-Heart
Infusion broth at 37 °C in a shaking incubator, except S.
pneumoniae which was grown in a 5% (v/v) CO2 atmos-
phere without shaking.
The lung cell lines used in this study were lines A549
(epithelial, ATCC® CRL-11185 ™) and MRC5 (fibroblasts,
ATCC® CRL-11171 ™). The two lines were grown in
DMEM and MEM, respectively, with the culture broth
being supplemented with 10% (w/v) fetal bovine serum
and penicillin G/streptomycin (5000 IU/ml, 5000 μg/ml).
Cultures were incubated at 37 °C in a 5% (v/v)
atmosphere.
Fluorescein labeling
FITC labeling of bacteria was carried out using over-
night cultures, which were washed four times with PBS
and resuspended in a 0.1 mg/ml FITC solution to an
A600 of 0.5; incubation in the dark at 37 °C under agita-
tion proceeded for 1 h, and then the bacterial suspen-
sions were centrifuged, washed 4 times with PBS to
eliminate the FITC excess, and resuspended in PBS to
an A600 of 0.5.
Adherence assays
Adhesion of the different pathogenic bacteria to A549
and MRC5 monolayers was performed in 24-well plates
grown to 70–90% confluence. The media were aspirated,
and the cells washed twice with PBS and then blocked
with 10% fetal bovine serum in PBS for 2 h at 37 °C in a
5% CO2 atmosphere. After further washing with PBS,
100 μl of FITC-labeled bacteria in 400 μl of DMEM was
added and the mixture incubated for 1 h at 37 °C and
5% CO2. Thereafter, the wells were rinsed (4 x) with
500 μl PBS to remove unbound bacteria. At the end of
the experiment, lung cells were disaggregated with 1%
SDS, and the fluorescence of the pathogens attached to
them was quantified in a Perkin Elmer LS55 fluorometer
set at 488 nm (excitation) and 560 nm (emission). Data
for the different experiments were normalized using the
adhesion values without any additive or treatment,
which was given the arbitrary value of 100%. Assays
were performed at least in triplicate and the data are
expressed as the mean ± SD.
Inhibition of glycosaminoglycan synthesis
Cell cultures in 24 well plates at approximately 70% con-
fluence were incubated in medium containing rhodamine
B 50 μg/ml or genistein 30 μM (final concentrations) over-
night at 37 °C. The cultures were washed twice with PBS,
and subjected to adherence assays as described in the pre-
vious paragraph.
Enzymatic digestion of lung cell-surface GAGs
Digestion of HS from cell cultures was achieved by incu-
bation at 37 °C for 3 h in a 5% CO2 atmosphere in min-
imal culture medium with a mix of 500 mU/ml (final
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concentration) each of heparinase I and III. Digestion of
CS chains was carried out by 3 h of incubation under
the same conditions, but using 250 mU/ml (final con-
centration) of chondroitinase ABC. The digestion of
both GAGs was performed through simultaneous incuba-
tion with heparinases I and III and chondroitinase ABC in
the same conditions. The reactions were stopped with 2
washes in PBS buffer and the cell cultures were immedi-
ately submerged in the appropriate supplemented culture
medium, and subjected to adherence assays with patho-
gens as described in the previous paragraph.
Adherence inhibition assays
The effect of GAGs on adherence interference experi-
ments was performed through the addition of either HS,
CS-A, CS-B, CS-C, or a mixture of all four, at concen-
trations ranging between 0.01 and 400 nM to the labeled
bacteria before their addition to the monolayers.
The effect of peptides which included the consensus
HP binding sequences, QKKFKN and FKKKYGKS on
adherence interference experiments was analyzed at a
final concentration of 20 nM of each peptide. The pep-
tides were added to the monolayers before the addition
of the labeled bacteria.
The effect of the location of sulfations in HS chains on
bacterial adherence was studied using native HP as con-
trol, and 2-O, 6-O and N-desulfated HPs at a final con-
centration of 20 nM as competitors in the adherence.
The HPs were added to the labeled bacteria before their
addition to the monolayers.
RNA isolation, cDNA synthesis and qRT-PCR reactions
RNA was isolated using the RNeasy kit following the
manufacturer’s specifications. Samples were subjected to
treatment with RNase-free DNase during the purifica-
tion process itself. The concentration of RNA obtained
was determined spectrophotometrically by measuring
absorbance using a Picodrop Microliter UV/Vis pectro-
photometer (Picodrop Limited, UK).
cDNA synthesis was carried out using the High Cap-
acity cDNA Transcription Kit following the manufac-
turer’s specifications. The reaction products were
cleaned using the PCR Clean-Up GenElute kit as per the
manufacturer’s instructions.
qRT-PCR reactions were carried out as previously de-
scribed [17], and actin was used as a control gene to com-
pare run variation and to normalize individual gene
expression. The expression values of genes were calculated
as 2–ΔCt (relative to actin as the housekeeping gene).
Antibody inhibition assays
Antibody inhibition assays were carried out in 24-well
plates grown to 80% confluence. The media was
aspirated, and the cells washed twice with PBS and then
blocked with 10% fetal bovine serum in PBS for 2 h at
37 °C in a 5% CO2 atmosphere. After further washing
with PBS, a mixture of anti SDC-1, anti SCD-2, anti
SDC-3, and SDC-4 were diluted 1:100 in PBS, except
anti-SDC2, which was diluted 1:250, and incubated for
1 h. After the treatment, adherence assays were per-
formed as indicated above.
Enzymatic removal of glypicans using phospholipase-C
Glypicans from cell surfaces were removed enzymatically
using PI-PLC. Cells were grown in 24-well plates to 80%
confluence. After washing with PBS, the cells were incu-
bated in the absence (control) or presence of 80 mU/ml
PI-PLC for 40 min at 37 °C in a 5% CO2 atmosphere.
After the treatment, adherence assays were performed,
as previously described.
Statistical analysis
All experiments were carried out at least three times,
with at least three replicates being used on each occas-
sion. All analyses were performed using the Statistics for
Windows program (Statsoft Inc.; Tulsa, OK). Mean
values were compared between two samples by the
Mann-Whitney U test and between multiple samples
using the Kruskal-Walis test. The p value accepted as
significant was p < 0.05. All data are presented as means
± standard errors of the means.
Results
GAGs are involved in the adherence of pathogenic
bacteria to lung cells
To analyze the possible involvement of GAGs in the ad-
hesion of some common lung pathogens, biosynthesis
inhibition experiments were performed in both lung fi-
broblasts and epithelial cells using two different com-
pounds that disrupt synthesis at different levels,
rhodamine B or genistein [32–35]. The cells treated with
the inhibitors were exposed to previously labeled patho-
gens in individual experiments, resulting in a decrease in
bacterial adherence in all cases, suggesting that GAGs
are involved in the binding of the pathogens in both
types of cell (Fig. 1a, b).
In epithelial cells, genistein displayed a statistically sig-
nificant higher inhibitory effect with all the bacteria
tested, with the exception of E. faecalis and K. pneumo-
niae (Fig. 1a). Similar results were obtained when MRC5
cells were analyzed, with genistein being the most effect-
ive at reducing the adherence of almost all bacteria, al-
though in this case rhodamine B showed higher
inhibition of S. pyogenes binding (Fig. 1b). When the
data were analyzed as a set, however, no significant dif-
ferences were observed in terms of type of inhibitor or
cell line used (Fig. 1c).
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Distinct GAG species are differentially involved in the
binding of pathogens to lung cells
The role played by the different molecular species of
GAGs in the adherence of pathogenic bacteria was stud-
ied using two strategies: the enzymatic degradation of
these molecules from the cell surface, and by binding
competition experiments with commercial GAGs.
The reduction of the levels of the different cell surface
GAGs of the A549 and MRC5 cell lines was carried out
using commercial bacterial lyases. All treatments, indi-
vidual or combined, produced a decrease in bacterial ad-
herence to lung cells (Fig. 2a, b).
In epithelial cells, the removal of both HS and CS by
lyases reduced bacterial binding in all cases. The use of
heparinases and the combination of all lyases showed
significantly stronger effects on the adherence of all bac-
teria than chondroitinase alone. The combination of ly-
ases decreased bacterial adherence to a similar extent as
treatment with heparinases, except in the binding of S.
marcescens, S. pneumoniae and K. pneumoniae, where
the inhibition effect was greater (Fig. 2a). However, ana-
lyzing the averaged data, the degradation of CS
produced a reduction in binding for all pathogens tested
of 19% (±6.68), while treatment with heparinases re-
sulted in an average reduction of 30% (±4.52), the differ-
ence between the two treatments being statistically
significant (p < 0.01) (Fig. 2c). The combined digestion
using both lyases decreased bacterial adherence by about
35% (±5.60) on average, which was only significantly dif-
ferent statistically with respect to the chondroitinase
treatment (p < 0.001) (Fig. 2c). These data suggest that,
in lung epithelial cells, both species are involved in ad-
herence, but that HS seems to play a more crucial role.
In a similar vein, in the fibroblast cell line, digestion
with bacterial lyases also caused a decrease in pathogen
binding. The mixture of enzymes showed the strongest
effect on binding in all cases, except S. marcescens and
E. faecalis. Comparing the data obtained after individual
use of heparinases or chondroitinase, significant differ-
ences were found in the case of the binding of S. aureus,
K. pneumoniae and S. pyogenes, where the removal of
HS showed an increased effect. For the remaining mi-
croorganisms, both types of enzymes decreased bacterial
adherence to similar degrees (Fig. 2b). When average
Fig. 1 Effect of the inhibition of GAG biosynthesis on pathogen adhesion to lung cells. a-b Effect of treatment with either rhodamine B or
genistein on binding to A549 cells (a) and MRC5 cells (b). c Relative differences in mean bacterial adherence inhibition between lung cells
treated with either rhodamine B or genistein. Data were normalized using values for adhesion of bacteria to non-treated cells, and spreads
represent standard deviation
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data were analyzed, treatment with chondroitinase ABC
reduced adherence by 30% (±7.20), while HS treatment
caused a decrease of around 35% (±7.51) (Fig. 2c). The
combination of both lyases decreased adherence by
more than 40%, although the differences between the ef-
fects obtained with lyases used individually and when
combined are not statistically significant (Fig. 2c). It
would thus seem that both types of GAG mediate in
bacterial binding to a similar extent, but that the role of
CS in the interaction between pathogen and fibroblast
appears to be more important than in epithelial cells.
Comparing the effects of degradation of HS and CS be-
tween both lung cell lines, statistically significant differ-
ences were only observed in the treatment involving
chondroitinase ABC (p < 0.05), which reduced adherence
of bacteria more in the MRC5 than the A549 cell line.
To further establish the influence of the several species
of GAGs as bacterial receptors in lung cells, diverse adher-
ence interference experiments were performed using com-
mercial HS, CS-A, CS-B, CS-C and an equimolar mixture
of each of them, as described in the Methods section. The
presence of GAG molecules decreased the binding of all
bacteria tested in both the A549 line (Fig. 3a) and the
MRC5 lines (Fig. 3b). Furthermore, in both lines adher-
ence was reduced in a dose dependent manner.
In epithelial cells, when commercial GAGs were used
individually, HS was the most effective interfering mol-
ecule. However, the role played by each type of CS var-
ied, depending on the pathogen tested (Fig. 3a). When a
mixture of all the GAGs was used, the effect obtained
was similar to when using HS, with the exception of S.
pneumoniae, which at low concentrations showed
greater inhibition of adherence by HS (Fig. 3a). While
no statistically significant differences between the mix-
ture of GAGs and HS were found, significant differences
were found between HS and CS-C (p < 0.05), as well as
between the mixture of all GAGs and each type of CS
individually (p < 0.05) (Fig. 3c).
In MRC5 cells, bacterial adherence was also reduced
by the different species of GAGs used individually and
by the mixture of GAGs (Fig. 3a). Comparing the indi-
vidual effects of each GAG type, HS displayed the high-
est inhibition effect on adherence in all pathogens
except S. marcescens, where CS-B showed similar values.
As in the epithelial cells, the effect of the different CS
species was dependent on the bacteria involved.
Fig. 2 Effect of enzymatic digestion of cell GAGs in bacterial adherence to lung cells. a-b Effect of pre-treatment with GAG lyases: heparinase I
and III, chondroitinase ABC and all enzymes simultaneously on bacterial adherence to A549 cells (a) and MRC5 cells (b). c Relative differences in
mean bacterial adherence between lung cells treated with each lyase individually, and with a combination of them all. Data were normalized
using the values for adhesion of bacteria to non-treated cells, and spreads represent standard deviation. Statistically significant differences are
denoted by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001
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Moreover, the effect of the equimolar mixture of GAGs
was similar to HS, the only exception being S. aureus,
where the combination of GAGs inhibited adherence
more effectively (Fig. 3a). Taken together the results evi-
dence that both, HS and the mixture of GAGs, showed
the highest inhibitory effect, and no statistically signifi-
cant difference was found between them (Fig. 3b).
However, the mixture of GAGs displayed significant
differences with every individual CS: CS-A (p < 0.01),
CS-B (p < 0.05) and CS-C (p < 0.05); significant dif-
ferences were also found between HS and CS-A
(p < 0.05) (Fig. 3b).
In contrast, when the effects observed for each interfering
molecule individually were compared to the impact of the
combination of all of them were compared, no differences
between the two types of lung cell were detected (Fig. 3c).
Differential interference of peptides with HP binding
sequences in the binding of pathogenic bacteria to lung
cells
Two peptides which include consensus HP binding se-
quences of different lengths, QKKFKN and FKKKYGKS,
were designed to examine their influence on bacterial
binding to lung cells. The effect of both peptides was
Fig. 3 Inhibition of pathogen attachment to lung cells in the presence of different GAGs. a Effect on adhesion to A549 cells and to MRC5 cells of
bacteria: Staphyloccocus aureus, Enteroccocus faecalis, Streptococcus pneumoniae, Streptoccocus pyogenes, Klebsiella pneumoniae, Escherichia coli, and
Serratia marcescens in the presence of different concentrations of each GAG individually and with a combination of all. b Comparative effect of the
various individual GAG species and a mixture containing all of them on mean bacterial adherence to the different lung cell lines. c Comparison
between lung cells with respect to the effect of the various different GAG species and a mixture of them all on mean bacterial adherence. Data are
shown normalized to a control represented by binding in the absence of interfering molecules. The spreads represent standard deviation. Statistically
significant differences are denoted by * for p < 0.05, and ** for p < 0.01
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first calibrated in our laboratory in adherence interfer-
ence experiments using S. aureus and S. marcescens.
The influence of both QKKFKN and FKKKYGKS was
dose-dependent, resulting in a reduction in binding up
to concentrations of 10–20 nM, diminishing their effects
at higher concentrations (data not shown). Conse-
quently, a concentration of 20 nM of each peptide was
selected for subsequent adhesion assays. The use of either
of the peptides caused a decrease in the binding of every
pathogen tested in both types of lung cell (Fig. 4a, b).
In the A549 line, despite both peptides reducing bac-
terial binding, the long peptide was significantly more ef-
ficient in all cases except K. pneumoniae, where values
were similar to those for the short peptide, and for E.
faecalis binding where the short peptide showed the
greater effect (Fig. 4a). Average values for the reduction
of adherence for the long peptide were 40% (±9.80),
while for short peptide they were 26% (±9.46). This ob-
served difference between the effect of the two mole-
cules, was analyzed and found to be significant only in
epithelial cells (p < 0.05) (Fig. 4c).
In contrast, in fibroblasts, the effect of individual peptides
depended on the pathogen in question. The long peptide
had a significantly stronger effect on reducing adherence of
S. pneumoniae, S. marcescens, K. pneumoniae and S. pyo-
genes, whereas the short peptide was more efficient in de-
creasing the binding of E. faecalis. Both peptides decreased
adherence to a similar extent for E. coli and S. aureus (Fig.
4b). Considering all the results together, adherence was re-
duced by 28.5% (±7.67) with the short peptide and 68.06
(±9.53) with the long peptide, though the difference was
not statistically significant (Fig. 4c).
Neither were significant differences found when compar-
ing the results of each peptide between the two cell types
(Fig. 4c).
Differential involvement of cell-surface HSPGs in the
binding of pathogenic microorganisms to lung cells
To determine which species of HSPGs were expressed in
both epithelial and fibroblast cell membranes, a transcrip-
tome study of the genes encoding the core proteins of all
the syndecan and glypican members was performed.
Fig. 4 Effect of peptides with heparin binding sequences on pathogen attachment to lung cells. The effects of QKKFKN and FKKKYGKS (20 nM
final concentration) on bacterial binding to A549 cells (a) and to MRC5 cells (b). c Relative differences in mean bacterial adherence inhibition
between lung cells in competition with each individual peptide. Data are shown normalized to the control represented by binding in the
absence of interfering molecules. The spreads represent standard deviation. Statistically significant differences are denoted by * for p < 0.05
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In A549 cells, transcripts for the four SDC isoforms
were detected with different levels of expression, isoform
1 and 4 being the most strongly expressed, and isoform
2 showing the lowest level of expression. Regarding tran-
scripts for GPCs, all six isoforms were also detected, but
the magnitude of expression levels found varied widely.
GPC-1 was the most abundant, with GPC-5 and -6 tran-
scripts being expressed at levels about one order of mag-
nitude, and those of GPC-2, −3 and −4 around three
orders of magnitude lower than levels GPC-1 (Fig. 5a).
In contrast, the arrangement of cell surface HSPG ex-
pressions in MRC5 cells was quite different: the four
syndecan isoforms all appeared highly transcribed, and
while the levels of the different glypican isoforms varied
between themselves by about three orders of magnitude,
similar to in the A549 cells, the pattern of expression
was quite distinct, particularly for GPC-2 and -4, which
expressed at higher levels (Fig. 5a).
To analyze the possible involvement of these families of
HSPGs in pathogen binding to lung cells, different adher-
ence essays were performed. To establish the role of GPCs
in the binding of pathogens, they were removed from the
cell surface using PI-PLC, an enzyme that cleaves their
GPI-anchor. The results showed that this treatment only
slightly decreased bacterial adherence in both A549 cells
(Fig. 5b), and MRC5 cells (Fig. 5c), for all pathogens. In
epithelial cells, binding was reduced by 4% (±3.52), and, in
fibroblasts by 6% (±5.19). Comparing the average values
obtained in each cell line, no great differences were de-
tected between epithelial cells and fibroblasts. (Fig. 5d).
The involvement of SDCs in bacterial adherence was
analyzed by blocking experiments using a combination of
specific antibodies against the four isoforms of these mol-
ecules. In all cases, in both epithelial and fibroblast cells,
this treatment decreased bacterial binding (Fig. 5b, c), by
27% (±10.32) in A549 cells and 28% (±6.31) in MRC5 cells
(Fig. 5d), the difference not being significant.
The analysis of the differences between PI-PLC and
anti-SDC treatments on each bacterium followed a
general pattern, which revealed the significantly
higher involvement of SDCs in binding to epithelial
cells (Fig. 5b). In terms of adherence to fibroblasts,
the differences between the two treatments were sta-
tistically significant for all bacteria (Fig. 5c).
Additionally, when all the data were analyzed, the dif-
ferences between PI-PLC and anti-SDC treatments on
bacterial adherence were significant for both cell lines
(p < 0.001) (Fig. 5d).
Influence of specific N- and O- sulfations on bacterial
adherence to lung cells
To analyze the influence of sulfation at specific positions on
the disaccharide unit of HS chains on interaction with bac-
teria, a variety of adherence interference experiments were
performed using 2-O, 6-O and N- desulfated HPs and com-
pared to normal HP as control. For all the pathogens tested,
the presence of any heparin-derived molecule diminished
binding, both to A549, and to MRC5 cells, although the re-
sults varied depending on the pathogen (Fig. 6).
In epithelial cells, desulfated HPs were less effective in
inhibiting the adhesion of all bacteria tested than fully
sulfated HP, although the scale of the effect varied de-
pending on the specific microorganism analyzed (Fig.
6a). Analyzing the effects of desulfated HPs for each bac-
terium the results showed similar values in S. aureus, K.
pneumoniae and E. faecalis. In the adherence of E. coli
and S. pyogenes 2 and 6-O-desulfated HP showed signifi-
cantly higher effects than N-desulfated HP whereas, 6-
O- and N-desulfated HP affected the bonding of S. mar-
cescens even more strongly, and 6-O-desulfated HP de-
creased the adherence of S. pneumoniae more than
other desulfated HPs did (Fig. 6a). Pooling all the data,
no significant differences were observed between in in-
hibition values for the three forms of desulfated HP
tested, although each showed significant differences
when compared to normal HP (p < 0.05) (Fig. 6c).
In fibroblasts, binding was also inhibited by the pres-
ence of each of the tested molecules, but in this case the
effect on the different pathogens was more homoge-
neous than in epithelial cells. As in the A549 cell line,
both when analyzing the data of each bacterium indi-
vidually, and when the set of all bacteria were considered
together, native HP displayed the highest inhibitory ef-
fect on adhesion in all cases, showing statistically signifi-
cant differences compared with each of the other
desulfated-HPs (p < 0.001) (Fig. 6b, c). Comparing the
individual effect of each desulfated HP, very different re-
sults were obtained depending on bacterium involved.
While no significant differences were found between the
effects of these molecules on the adherence of S. pneu-
moniae and S. marcescens, 6-O-desulfated HP showed
the highest effect on binding for S. pyogenes, S. aureus
and E. faecalis. 6-O- and N-desulfated HP reduced
bonding of E. coli more significantly, and N-desulfated
HP showed significant differences with 2-O-desulfated
HP in the case of K. pneumoniae (Fig. 6b). However, re-
garding the average data, in these cells differences
dependent on the type of sulfation were detected, with
6-O-desulfated HP able to compete more effectively than
2-O-desulfated HP (p < 0.05), while N-desulfated mole-
cules produced more heterogeneous results (Fig. 6c).
Discussion
PGs are involved in many infectious processes, especially
by their GAG moieties, which act as receptors for the
adherence and attachment of many pathogenic microor-
ganisms, including some which affect the respiratory
tract [24, 26]. Lung epithelial cells are in contact with
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the environment, creating a barrier against pathogens,
along with the other passive and active defense mecha-
nisms. Lung fibroblasts are found in the lower layers,
and are thus less exposed to environmental factors and
microorganisms. It would therefore be expected that
both cell types present a distinct profile of PGs, includ-
ing GAGs, with different structures, which would affect
their interaction with pulmonary pathogens. The
characterization of GAG-pathogen interactions could
allow new and more efficient infection avoidance strat-
egies to be developed via preventing adhesion.
To determine the involvement of PGs, and especially
their GAG moieties, in bacterial attachment to A549
and MRC5 cell lines, their levels were reduced by the
Fig. 5 Involvement of cell surface HSPGs in the binding of pathogens to lung cells. a Differential transcription of syndecans and glypicans in lung
cells; values on the Y-axis are represented on a logarithmic scale. b-c Effect of treatment with anti-SDC antibodies and with PI-PLC on pathogen
attachment to A549 cells (b) and MRC5 cells (c). d Relative differences in mean bacterial adherence inhibition between lung cells treated with
anti-SDC antibodies and with PI-PLC. Data are shown normalized to the control represented by binding in the absence of treatment. The spreads
represent standard deviation. Statistically significant differences are denoted by *** for p < 0.001
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use of two specific inhibitors of their biosynthesis:
rhodamine B or genistein, and the effect on pathogen
adherence analyzed. These treatments resulted in a sig-
nificant decrease in bacterial adherence in all cases,
indicating that the lung pathogens use, at least in part,
GAGs as receptors for adhesion. We have recently pub-
lished a study of bacterial adherence to corneal epithe-
lial cells, where it was noted that treatment with
rhodamine B or genistein had a different effect on bac-
terial adherence depending on the Gram nature of the
microorganism in question. Specifically we found that
in Gram-positive bacteria binding was most affected by
rhodamine, while genistein more strongly reduced
Gram-negative adhesion [36]. Interestingly, the current
study was unable to determine the existence of such
patterns in the adherence of microorganisms to lung
cell lines, being the behavior observed dependent, for
each specific cell line, of the bacterial species analyzed.
The results observed may be due to the fact that these
molecules affect the biosynthesis of GAGs at different
levels. Rhodamine B is thought to inhibit chain elong-
ation, acting as a nonspecific inhibitor that reduces
GAG synthesis in a range of cells, and produces reduced
lysosomal GAG storage in some types of mucopolysac-
charidosis [32, 33]. The isoflavone genistein inhibits the
kinase activity of epidermal growth factor receptor,
which is required for the full expression of genes coding
for enzymes involved in GAG production [34], although
it has been described that the effect of this molecule on
the biosynthesis of GAGs is strongly dependent on their
type and localization [35]. Each bacterium has different
types of adhesins to bind to the chains of GAGs of lung
cells, and each one of these molecules has a variable
binding specificity, which can be determined by various
factors, such as the length of the chains, which would be
affected by rhodamine B, or by the structure of the GAG
chains, which can be altered by treatment with genistein.
The involvement of GAG species in bacterial adherence
to lung cells was analyzed by reducing the levels of GAG
chains by means of enzymatic degradation using bacterial
lyases. The results show that both types of GAG are in-
volved in the binding of bacteria to lung cells. In A549 cells,
heparinase treatment significantly decreased adherence
relative to chondroitinase treatment, but not compared
Fig. 6 Influence of specific N- and O- sulfations on pathogen adherence to lung cells. a-b Inhibition of the binding of microorganisms to A549
cells (a) and MRC5 cells (b) by the presence of native heparin, 2-O desulfated heparin, 6-O-desulfated heparin and N-desulfated heparin. c Comparative
effect of the different heparins on mean bacterial adherence to lung cells. Data are shown normalized to the control represented by binding in
the absence of interfering molecules. The spreads represent standard deviation. The differences between native HP and desulfated HPs are
not shown in the figure, being all of them significant. Statistically significant differences are denoted by * for p < 0.05, and *** for p < 0.001
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with simultaneous digestion of HS and CS chains, suggest-
ing that HS is the main species involved in bacterial adher-
ence, and that there is no additive effect in the presence of
both molecules. In MRC5 cells, HS also seems to be the
principal molecule involved in adherence, but in this case,
chondroitinase treatment produced a similar decreases as
HS with respect to certain bacteria, suggesting that in this
cell line CS has a greater involvement in bacterial adhesion.
The differences observed in chondroitinase treatment for
both cell lines were statistically significant, which could be
a reflection of the existence of differences between A549
and MRC5 cell lines as regards PG composition and struc-
ture of GAG chains, considering that the expression pattern
of GAGs varies depending on cell type and their physio-
logical state.
The participation of the predominant GAG species
present on the cell surface in the adhesion of pathogens
was also studied by analyzing their ability to compete in
adherence interference experiments. HS showed the high-
est inhibitory ability, suggesting that it constitutes the pre-
dominant cell surface receptor for all the bacteria
analyzed, although in the case of binding of S. marcescens
to fibroblasts, CS-B showed an effect comparable to HS.
There was no clear pattern in the inhibition produced by
the diverse types of CS tested in both epithelial cells and
fibroblasts depending on the bacteria tested. When the in-
hibitory effect of an equimolar mixture of all the GAG
species was analyzed, in most cases results were similar to
HS used alone, suggesting, again, that this species is the
main cell surface receptor. An interesting exception to the
previous conclusion was the binding of S. aureus to fibro-
blasts, where the effect of the mixture was considerably
higher than that produced by HS alone, suggesting that in
this cell type different molecular species cooperate in the
binding of the pathogen.
All the results obtained in this work suggest HS to be
the main mediator in bacterial cell adhesion, which fits
with the fact that it is the most widespread GAG on cell
surfaces [12, 13]. A large number of bacteria use this
molecule as a receptor for adhesion to different tissues,
including Helicobacter pylori, E. faecalis, Neisseria
meningitidis, Pseudomonas aeruginosa, and S. aureus,
among others [24]. Other GAGs are also able to act as
receptors for microorganisms, such as Borrelia burgdor-
feri, which uses a variety of these molecules as receptors
depending on the host cells; HS to bind to endothelial
cells and CS-B and HS to glial cells [37]. HS and CS-B
chains also mediate in Chlamydia trachomatis, S. pyo-
genes binding [24]. Both HS and CS-B share a feature in
their chemical structure, variable proportions of the C-5
epimer of glucuronic acid, the iduronic acid, providing
the molecule with more flexibility [38]. Some of the
most common pathogenic bacteria in the respiratory
tract also use GAGs, mainly HS, for attachment, such as
S. pneumoniae [39], 75% of nontypeable Haemophilus
influenzae [40], Chlamydia pneumoniae, and P. aerugi-
nosa on basolateral epithelial surfaces [24].
HS has a complex domain structure, consisting of
highly sulfated NS-domains interspaced with poorly sul-
fated NA-domains. Most interactions between proteins
and HS occurs mainly through NS-domains, either by
electrostatic interactions or by the specific recognition
of sulfated sequences in saccharide chains. Most
heparin-binding proteins have clusters of basic amino
acids alternating with hydropathic residues that have
been shown to be required for binding [41]. In accord-
ance with these consensus sequences, two peptides,
FKKKYGKS and QKKFKN, were designed in order to
figure out their role as competitors for bacterial attach-
ment and, consequently, their ability to mimic different
binding motives present on the bacterial adhesins. Both
peptides partially inhibited adhesion in both cell lines,
and in most cases the longer peptide was more efficient.
However, the pattern observed changed depending on
the bacteria and, particularly, on the pulmonary cell
type, suggesting that different bacterial adhesins with
different HP binding sequences are mediating in inter-
action with lung cells [8, 42, 43].
Generally, HS chains occur as HSPGs, and two gene
families, SDCs and GPCs, account for most cell surface
HSPGs. Some previous studies have related specific spe-
cies of cell surface HSPGs with the adhesion of and
colonization by certain pathogens [7, 14, 42]. Since
HSPGs are expressed in varying amounts depending on
the tissue, we quantified their transcript levels in both
lines of pulmonary cell. In the MRC5 line, transcripts for
the four SDCs could be detected at similar levels, but in
the A549 line isoforms 1 and 4 were much more abun-
dant. With respect to GPCs, the six isoforms showed
large differences in their transcript levels, dependent on
the cell type, although isoform 1 was the most abundant
in both cases. The enzymatic removal of GPCs from the
cell surface did not show any great effect, while blocking
experiments with a combination of anti-SDC specific
antibodies resulted in a decrease in adherence in both
cell lines, suggesting that SDCs are involved in bacterial
attachment to lung cells.
Similar results were found in a study of bacterial adhe-
sion to corneal epithelial cells, where all the isoforms of
SDCs participate cooperatively in the attachment of bac-
teria, indicating that they play a far more important role
in this process than GPCs [36]. The involvement of
SDCs in bacterial adherence has been described for dif-
ferent pathogens such as Streptococcus agalactiae, Lis-
teria monocytogenes and S. aureus, which interacts with
syndecan-1 for adherence to cells; and Neisseria gonor-
rhoeae, whose adhesin OpaA uses SDC-1 and -4 as re-
ceptors [44–46]. There is little information on the
Rajas et al. BMC Infectious Diseases  (2017) 17:319 Page 12 of 14
involvement of GPCs in infectious processes, an interest-
ing exception being the case of the intracellular patho-
gen Chlamydophila pneumonia, which is able to use a
variety of cell-type specific binding mechanisms, e.g. it
uses GAG chains to bind to epithelial cells, but in Jurkat
lymphoid cells, which only express GPC-1, it uses a
GAG-independent mechanism to bind. However, it is
known that GPCs are involved in other non-infectious
diseases, including tumoral processes, neurological syn-
dromes and disorders, and prion diseases [22, 47–50].
In some pathogens, it has been described that specific
patterns of sulfation are required for adherence; this is
the case for C. trachomatis, whose binding to HeLa 229
cells is inhibited by 2-O desulfated HP [51], certain vi-
ruses such as the hepatitis E virus, which interacts with
6-O-sulfated HS [52], and baculovirus, whose entrance
is promoted by 6-O-and N-sulfated HS [53]. To investi-
gate the importance of specific sulfated positions of the
HS disaccharide unit on the binding of bacteria to lung
cells, the effect of native HP compared to 2-O, 6-O and
N-desulfated HPs in competition adherence assays was
analyzed.
All desulfated HPs showed less inhibitory capacity
than the native HP, which points to the importance of
sulfation in adherence. However, the effect was slightly
different between the two cell lines; while in the epithe-
lial cells results varied widely depending on the pathogen
analyzed, and no significant differences between the dif-
ferent desulfated heparins were observed, in fibroblasts
results were more homogeneous, and sulfation in C2 of
uronic acid showed a greater effect on competition sulfa-
tion in C6 of the glucosamine residue. These data sug-
gest that binding involves different sulfated sequences in
each cell type, which could also relate to the use of dif-
ferent bacterial adhesins in each case.
Conclusions
In summary, this work describes that GAGs seem to be
implicated in the binding of different pathogenic bacteria
both to epithelial cells and to lung fibroblasts. HS seems
to be the principal GAG species involved, especially
when conjugated in SDCs. But the molecular features of
the binding seems to be dependent on the bacteria and,
particularly, on the type of pulmonary cell involved,
which appear to involve different HS sulfation patterns
and different bacterial adhesins. Increased understanding
of the relation between bacteria and their receptors, es-
pecially HS, and the influence of certain details of its
structure, may lead to opportunities for developing in-
novative and selective therapies in the future. From this
perspective, the structure of the GAG molecules and
their implication in interactions with microorganisms
deserve further investigation into their possible thera-
peutic role in a variety of pulmonary infections.
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